Abstract-The aim of the study was to investigate whether diverse clinical blood pressure phenotypes are associated with free leptin surrogates, as reflected by plasma leptin, human soluble leptin receptor, and their ratio (ie, free leptin index) in nonobese normoglycemic subjects. Three separate clinic blood pressure measurements and ambulatory blood pressure monitoring were implemented to divide 494 subjects (aged 44Ϯ5 years; 272 men; body mass index: Ͻ30 kg/m 2 ) into hypertensives (nϭ166), white-coat hypertensives (nϭ82), masked hypertensives (nϭ66), and normotensives (nϭ180). Participants underwent echocardiography, while, from fasting venous blood samples, metabolic profile, plasma leptin, and its receptor levels were assessed. Hypertensives and masked hypertensives demonstrated higher levels of log (10)(leptin) and log (10)(free leptin index), as well as lower levels of log (10)(human soluble leptin receptor) with respect to normotensives. White-coat hypertensives had similar free leptin surrogates compared with normotensives. Younger age, 24-hour systolic and diastolic blood pressures, 24-hour heart rate, and left ventricle mass index were common correlates of free leptin surrogates. After adjustment for confounders, masked hypertensive and hypertensive with respect to normotensive phenotype were associated with log (10)(leptin) with odds ratios (95% CIs) of 1.31 (1.12 to 3.80) and 1.26 (1.09 to 2.24), respectively, log (10)(human soluble leptin receptor) with 0.65 (0.53 to 0.78) and 0.69 (0.57 to 0.84), respectively, and log (10)(free leptin index) with 2.46 (1.32 to 7.23) and 1.84 (1.26 to 3.73), respectively (PϽ0.05 for all of the cases). Free leptin surrogates are associated with masked hypertension in nonobese normoglycemic subjects. Free leptin is almost equally increased in masked and sustained hypertension, suggesting a similar leptin-related vascular impairment. (Hypertension. 2009;53:00-00.) Key Words: leptin Ⅲ human soluble leptin receptor Ⅲ masked hypertension Ⅲ clinical blood pressure phenotypes Ⅲ hypertension I ncreased leptin levels have been independently associated with cardiovascular diseases 1 and risk factors such as obesity, insulin resistance, type 2 diabetes mellitus, 2 as well as with blood pressure (BP) levels even below the clinically defined hypertensive cutoff value. 3,4 Leptin may be implicated on the perpetuation of systemic inflammation given its modulator effect on C-reactive protein 5 and its structural and functional resemblance to proinflammatory cytokines like interleukin 6. 6 Because between hypertension and systemic inflammation there is an established reciprocal pathophysiological link, 7 hyperleptinemia might be implicated on the adverse hemodynamic regulation beyond the centrally obesity-mediated mechanisms of leptin resistance. 8 Although in vivo studies supported the notion that chronic hemodynamic actions of leptin are likely attributable to widespread sympathoactivation of metabolically active tissues and not to the vasculature to increase vasomotor tone, 9 in vitro evidence suggested that leptin at concentrations higher than the physiologically relevant level may exert adverse effects on the vasculature by peripheral actions, eg, stimulation of reactive oxygen species, impaired NO production, renal sodium retention, increased endothelin 1 synthesis, transactivation of epidermal growth factor receptor, and inhibition of angiogenesis, promoting, at least partly, BP elevation. 10 -14 Leptin, by acting on the membrane-bound leptin receptor and by the interaction with diverse mediators and regulators, stimulates autonomic nervous system activity and regulates appetite, energy expenditure, and peripheral insulin actions. 15 Membrane-bound isoforms of the leptin receptor produce by cleavage the soluble form of the leptin receptor (human soluble leptin receptor [hs-LR]), proposed as a regulator of leptin activity. [15] [16] [17] The ratio between the concentration of leptin and hs-LR is the free leptin index (FLI), a balance surrogate between leptin and hs-LR. 18 It has been hypothesized that increased leptin in tandem with decreased hs-LR levels observed mainly in obese subjects would constitute
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Methods

Study Design
A cross-sectional design was chosen to compare plasma leptin, hs-LR, and FLI among different clinical BP subgroups. A careful medical history was obtained, and all of the participants were also given clinical and echocardiographic examinations. Apart from a strictly scheduled clinic BP evaluation, ambulatory BP monitoring, and routine biochemical profile assessment complemented by oral glucose tolerance testing, we performed plasma leptin and hs-LR measurements. The study protocol complies with the Helsinki Declaration, was approved by our institutional ethics committee, all of the participants gave written informed consent, and data were evaluated anonymously.
Participants
We studied 622 consecutive never-treated white subjects, aged Ն30 years, with body mass index Ͻ30 kg/m 2 who were self-referred to our outpatient hypertensive clinic for BP evaluation. Diagnosis of hypertension was made in 236 subjects presenting a mean clinic BP Ͼ140/90 mm Hg in 3 separate visits subsequently confirmed by daytime BP Ͼ135/85 mm Hg. In addition, 92 subjects labeled as white-coat hypertensives demonstrated mean clinic BP Ͼ140/ 90 mm Hg associated with daytime BP Ͻ135/85 mm Hg. Masked hypertension (mean clinic BP Ͻ140/90 mm Hg with ambulatory daytime BP Ͼ135/85 mm Hg) occurred in 84 subjects, whereas the remaining population was considered normotensive (nϭ210). 22 We excluded subjects with diabetes mellitus (ie, treatment with antidiabetic drugs or plasma glucose levels Ͼ125 mg/L [nϭ15]), impaired glucose metabolism (ie, fasting plasma glucose levels Ͼ110 mg/dL associated with an abnormal oral glucose tolerance test [nϭ20]), and familial dyslipidemia (nϭ10), as well as those with a history of any cardiovascular disease (nϭ40); secondary hypertension, including obstructive sleep apnea (nϭ9); and any other clinically significant concurrent medical condition (thyroidal, psychiatric, neuromuscular, kidney, respiratory, hepatic, or gastrointestinal disease [nϭ6]). Participants with a history or clinical/laboratory evidence of recent infection, inflammation, or who underwent any medical treatment (including lipid lowering, nonsteroidal antiinflammatory, and hormone replacement therapy) 1 month before entry in the study were also excluded (nϭ16). Furthermore, 12 subjects, although eligible to participate, refused to give informed consent. After the implementation of the above during the recruitment period, the population eligible to participate consisted of 494 subjects with diverse BP clinical phenotypes (ie, sustained hyperten- 
Measurements
Clinic and Ambulatory BPs
BP measurement was made at 3 separate visits with a mean elapsing time of 1 week. 22, 23 In each visit, participants were encouraged to relax for Ϸ10 minutes, and, subsequently, in a quiet room with a stable temperature and luminosity, an experienced cardiologist, after having explained the procedure to the participants, performed 3 different BP measurements at 5-minute intervals by using a mercury sphygmomanometer. Korotkoff phases I and V were used to determine the systolic and diastolic BP components, respectively; in each visit, the second and third BP measurements were averaged, and the final BP consisted of the mean of the 3 visits. Mean clinic heart rate was determined by averaging the 3 separate registered values of heart rate. Over a working day (Monday through Friday) and after the completion of clinic BP measurements, ambulatory BP was recorded by using the automatic SpaceLabs units 90207 by means of a procedure described previously in detail. 24 In brief, the cuff with the appropriate bladder size was fixed to the nondominant arm, and the device was set to obtain automatic heart rate and BP readings at 15-minute intervals during the daytime and at 30-minute intervals during the nighttime. Daytime and nighttime were defined using short, fixed clock time intervals, which ranged from 10 AM to 8 PM and from 12 AM to 6 AM, respectively. Investigators performing ambulatory BP monitoring were blinded to the clinical status of the examinees. Twenty-four-hour systolic/diastolic BP and heart rate values were the mean of the overall 24-hour recordings after artifact editing. More than 80% of successful readings were required to include a test as adequate for subsequent analysis. Subjects with a nighttime BP fall Ͼ10% were defined as dippers and those with Ͻ10% as nondippers.
Cardiac Ultrasonography
The echocardiographic study was performed by an experienced senior operator who was blind to the clinical status of the examined subject using a General Electric Medical System Vivid 3 PRO ultrasound imager equipped with a 2.5-to 5.0-MHz transducer, according to the guidelines of the American Society of Echocardiography. 25 Left ventricle mass was measured by using the formula of Devereux indexed for body surface area to estimate left ventricle mass index, whereas relative wall thickness was calculated using the appropriate formula. 26 
Biochemical Assessment
Venous blood samples were obtained from each participant after an overnight fasting (from 6 AM to 8 AM) for the determination of serum glucose level, serum creatinine level, and lipid profile (ie, total cholesterol, triglycerides, and low and high lipoprotein cholesterol), according to established methods. Estimated glomerular filtration rate was assessed according to the 4-variable isotope dilution mass spectrometry-traceable Modification of Diet in Renal Disease Study equation. 27 An oral glucose tolerance test was performed in all of the participants according to established procedure. Part of the blood specimens after centrifugation was stored at Ϫ80°C until analyzed; plasma immunoreactive leptin (nanograms per milliliter) was measured by radioimmunoassay (Human Leptin radioimmunoassay kit, Linco Research Inc), whereas plasma hs-LR (UI per milliliter) was measured by immunosorbent assay (ELISA; Human Leptin Receptor ELISA, Bio Vendor Inc). Samples were run in duplicate with an average coefficient of variation between runs of 7.5% for leptin and 6.0% for hs-LR. FLI was calculated by the ratio of leptin:hs-LR concentrations.
Statistical Analysis
The SPSS statistical package, release 15.0 (SPSS Inc) was used for all of the statistical analyses. All of the descriptive continuous variables are presented as means and SDs if their distribution was normal (Shapiro-Wilk test), whereas the nonnormally distributed variables are presented as medians and ranges. Because of their skewed distribution, leptin, hs-LR, and FLI values were logarithmically (log10) transformed before testing. Categorical variables are described with absolute and relative (percentages) frequencies.
Significant differences between the groups were determined using the Student's independent samples t test after checking for equality of variances using the Levene's test and ANOVA. To adjust for the inflation of type I error because of the high amount of multiple comparisons, we used the Bonferroni correction. Because there were 4 groups, 6 pairwise comparisons were possible, and the differences were considered significant if the P value was Ͻ0.008. Spearman's correlation coefficients were calculated to assess univariable associations between free leptin surrogates with diverse cofactors. Simple bivariate correlation analysis was performed using the Pearson r correlation coefficient where appropriate.
Conditional linear multivariable regression analysis was used to examine the significant correlates of the logarithmically transformed leptin, hs-LR, and FLI. The candidate explanatory independent variables entered into the models were those that demonstrated significant correlation in the univariable analysis, whereas age and sex were implemented by forced entry into the models. To validate our linear multivariable models, we tested the normality and heteroscedasticity of the residuals produced. Any potential multicollinearity between the explanatory variables was tested by calculating the variance inflation factor and tolerance (1/variance inflation factor). No multicollinearity was found, because tolerance values were Ͼ0.1. Thereafter, we performed a multinomial logistic stepwise (forward entry) regression analyses to test whether the log(10) transformed free leptin surrogates were determinants of diverse clinical BP phenotypes by using as a reference the normotensive phenotype after adjustment for confounders. Determinants were also standardized for their SDs (z scores) to compare the magnitude of their associations.
On the basis of previous data from our hypertensive clinic, a number of Ն66 subjects from each group was adequate to detect a 2-sided mean difference Ͼ0.5 between subgroups and the investigated outcome variables achieving statistical power Ͼ90% at the 5% probability level (P value). Table 1 presents the demographic and clinical characteristics of the study population, whereas Table 2 presents the biochemical and echocardiographic data. Although the groups demonstrated similar demographic characteristics, including body size, the different hemodynamic load registered by both clinical and ambulatory measurements was extended in the nighttime but without any difference regarding the dipping status. Between subgroups with diverse clinical BP phenotypes, kidney function and metabolic parameter results were similar, including 2-hour plasma glucose levels during tolerance glucose testing, whereas left ventricle mass and geometry differed significantly.
Results
Hypertensive compared with normotensive subjects presented higher log(10)(leptin) and log(10)(FLI) levels, whereas log(10)(hs-LR) was decreased in the former group with respect to the latter (PϽ0.001 for all). In addition, hypertensives compared with masked hypertensives had similar levels of log(10)(leptin) and log(10)(FLI; PϾ0.008 for both cases) but demonstrated lower levels of log(10)(hs-LR; Pϭ0.002), whereas, compared with white-coat hypertensives, the presented higher levels of log(10)(leptin) and log(10)(FLI) and lower levels of log(10)(hs-LR; PϽ0.001 for all cases). White-coat hypertensives compared with masked hypertensives demonstrated higher levels of log(10)(hs-LR; PϽ0.001) and lower levels of log(10)(leptin) and log(10)(FLI; PϽ0.001 for all cases; Table 2 ). Table 3 provides the Spearman univariable associations of log(10)(leptin), log(10)(hs-LR), and log(10)(FLI) with a variety of cofactors. Interestingly, the associations of log(10)(hs-LR) with the studied cofactors were of the inverse direction with respect to those of the remaining free leptin surrogates. Pearson's r coefficient for the interrelationships between log(10)(leptin) with log(10)(hs-LR) and log(10)(FLI) was Ϫ0.50 and 0.88, respectively (PϽ0.001 for both).
Table 3. Spearman's Univariable Correlations of Log(10)(Leptin), Log(10)(hs-LR), Log(10)(FLI), and Cardio-Metabolic Risk Factors
We performed 3 diverse conditional linear multivariable regression models (Table 4 ) using as a dependent variable log(10)(leptin; overall model fit: R 2 adjustedϭ27.6%; PϽ0.001), log(10)(hs-LR; overall model fit: R 2 adjustedϭ35.3%; PϽ0.001), and log(10)(FLI; overall model fit: R 2 adjustedϭ38.3%; PϽ0.001), respectively. Common significant correlates for all of the logtransformed leptin surrogates were 24-hour systolic/diastolic BPs, 24-hour heart rate, younger age, waist circumference, and left ventricle mass index, whereas additional significant correlates for log(10)(leptin) were female sex and low-density lipoprotein cholesterol and for log(10)(FLI) were plasma glucose and low-density lipoprotein cholesterol.
Finally, by using multinomial logistic multivariable models, both sustained hypertension and masked hypertension were independently associated with free leptin surrogates after adjustment for cofactors (Table 5) . Also in Table 5 we present the magnitude of the above associations by means of z scores; hypertensive and masked hypertensive phenotypes were more strongly associated with log(10)(FLI) with respect to the associations with either log(10)(leptin) or log(10)(hs-LR). (10)(Leptin), Log(10)( hs-LR) , and Log(10)(FLI) 
Discussion
The novel finding of the present study is that the presence of masked hypertension was associated with increased plasma leptin and decreased hs-LR levels independent of confounders, including body size and metabolic parameters, whereas white-coat hypertensive phenotype did not demonstrate a comparative association. The out-of-clinic hypertensive BP phenotypes identified either as sustained or as masked hypertension reflected an adverse circulating leptin molecular network with possible adverse effects on the vasculature. This is the first study examining systematically the association of diverse BP clinical phenotypes with free leptin surrogates. There is evidence that increased free leptin levels predict the future development of hypertension, 28 and we have demonstrated previously that the healthy offspring of hypertensives are characterized by hyperleptinemia, 29 suggesting that hyperleptinemia may precede and contribute to the development of hypertension, rather being secondary to the increased BP. Furthermore, our previous finding that hyperleptinemia and decreased levels of circulating leptin receptor are associated with high-normal BP with respect to optimal BP in lean subjects 20 is confirmed by the present study in a larger group of subjects, suggesting that the "circulating free leptin duo" may represent an obscured bloodstream molecular hemodynamic accelerator.
Experimental studies have shown that the effects of leptin on the vasculature are nonlinearly dose dependent and that increased hormone levels proved detrimental with respect to lower but still physiologically relevant concentrations. 1, 10 The circulating leptin receptor could modulate the steady-state leptin by complexing free leptin in circulation and consequently preventing the hormone from degradation and clearance. 17 Consequently, lower hs-LR levels in the context of hyperleptinemia may contribute to the detrimental actions of the hormone on the vasculature, as has been hypothesized by others, 13, 14, 18, 19 and in hypertension the protective vascular threshold of the leptin concentration could be regulated at a lower level. The integrated surrogate of circulating leptin as expressed by FLI was better associated with adverse clinical BP phenotypes than leptin levels alone, suggesting that leptin and its circulating receptor may be implicated conjointly to the pressor effects of the hormone.
So far, studies implicating animal models supported the notion that leptin, by acting centrally, enhances sympathetic activity. 8, 30, 31 Accordingly, leptin has been considered a systemic sympathetic-mediated pressor lever resembling the clinical model of obesity-related hypertension. 8 On the other way around, it is yet unresolved whether the increased hemodynamic load, per se, promotes hyperleptinemia 32, 33 or whether a functional intermediate link, eg, subclinical inflammation 5, 6 and/or endothelial dysfunction, [12] [13] [14] 34 could separately or in combination contribute to the association proposed by the present study. A recent experimental study in obese animals concluded that the inhibition of central leptin signaling was insufficient to reverse obesity-induced hypertension and that the peripheral effects of leptin may be more important in mediating hypertension than stimulation of the sympathetic nervous system centrally. 35 Although there is evidence supporting the idea that leptin does not have a direct effect on resistance vessels in vivo, 9 the interplay between BP levels and free leptin may share a reciprocal modulation with sympathetic activation, systemic subclinical inflammation, and endothelial dysfunction, anticipating adverse BP clinical phenotypes, including masked hypertension, with possible adverse repercussion on cardio-metabolic outcomes. 36, 37 Indeed, a previous study among hypertensive insulin-resistant subjects found increased leptin levels associated with left ventricle hypertrophy, whereas our findings extended the A reference category for the dependent variable was considered the normotensive BP phenotype. Cofactors entered in all of the models were age, sex, smoking status, waist circumference, 24-h systolic and diastolic BPs, 24-h heart rate, low-density lipoprotein cholesterol, plasma glucose, estimated glomerular filtration rate, and left ventricle mass index. z scores reflect the comparative magnitude of the determinants after adjustment for confounders entering into each model. latter observation in masked hypertension and in those without glycemic impairment. 38 The cross-sectional nature of our study limits the ability to infer any causal or temporal relationship between free leptin with masked hypertension. Furthermore, given that our sample consisted of subjects of European decent, prevalently middle aged, with body mass index Ͻ30 kgr/m 2 and without any treatment who were referred to our hypertension clinic, the results could not be directly extendable in other ethnicities, different ages, and different body adiposity groups or to subjects under antihypertensive treatment or in the general population. Although, we excluded the peripheral component of insulin resistance, the central one related to fasting insulin levels could not be ruled out definitively. In the same lines, the exclusion of those with impaired fasting glucose and the impaired glucose tolerance test makes the findings relevant only in normoglycemic subjects.
Perspectives
Further clinical studies are needed to confirm the possible prognostic value of free leptin on BP levels, including the determination of the physiologically relevant concentrations of the measure in humans associated with adverse clinical BP phenotypes. The finding that hs-LR assessment further contributes to the identification of adverse clinical BP phenotypes with respect to the measurement of leptin alone suggests that the hemodynamic modulation of leptin is at least partially related to its free receptor availability; to test the latter hypothesis, studies examining integrated leptin surrogates in relationship to BP-lowering treatment would provide further evidence accordingly. Finally, the prolongation of leptin half time by enhancing its circulating receptor availability would be an emerging molecular target for diminishing the adverse pressor effects of free leptin.
In conclusion, masked hypertension is associated with increased plasma leptin and decreased hs-LR levels in nonobese normoglycemic subjects. Although white-coat hypertensive and normotensive phenotypes are associated with a more favorable free leptin pattern, masked hypertension and sustained hypertension are characterized by almost the same levels of free leptin enhancement, suggesting similar leptinrelated impairment on the vasculature.
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